CONSIDERATIONS TO KNOW ABOUT ABBV-744 BRD4 INHIBITOR CANCER THERAPY EFFICACY

In Section C, contributors will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment till disease progression or perhaps the contributors are unable to tolerate the study drugs.88 These preclinical studies offer paradigms for foreseeable future clinical trials in AML, and us